Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas

J. I.Ichiro Sasaki; Kenneth K. Tanabe; Kazuhisa Takahashi; Isamu Okamoto; Hisao Fujimoto; Mitsuhiro Matsumoto; Moritaka Suga; Masayuki Ando; Hideyuki Saya

doi:10.3892/ijo.12.3.525

Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas

J. I.Ichiro Sasaki
, Kenneth K. Tanabe
, Kazuhisa Takahashi
, Isamu Okamoto
, Hisao Fujimoto
, Mitsuhiro Matsumoto
, Moritaka Suga
, Masayuki Ando
, Hideyuki Saya

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

Original language	English
Pages (from-to)	525-533
Number of pages	9
Journal	International journal of oncology
Volume	12
Issue number	3
DOIs	https://doi.org/10.3892/ijo.12.3.525
Publication status	Published - 03-1998
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.3892/ijo.12.3.525

Cite this

@article{57f478118216470a859b1a9ff4fa4561,

title = "Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas",

abstract = "We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.",

author = "Sasaki, \{J. I.Ichiro\} and Tanabe, \{Kenneth K.\} and Kazuhisa Takahashi and Isamu Okamoto and Hisao Fujimoto and Mitsuhiro Matsumoto and Moritaka Suga and Masayuki Ando and Hideyuki Saya",

year = "1998",

month = mar,

doi = "10.3892/ijo.12.3.525",

language = "English",

volume = "12",

pages = "525--533",

journal = "International journal of oncology",

issn = "1019-6439",

publisher = "Spandidos Publications",

number = "3",

}

TY - JOUR

T1 - Expression of CD44 splicing isoforms in lung cancers

T2 - Dominant expression of CD44v8-10 in non-small cell lung carcinomas

AU - Sasaki, J. I.Ichiro

AU - Tanabe, Kenneth K.

AU - Takahashi, Kazuhisa

AU - Okamoto, Isamu

AU - Fujimoto, Hisao

AU - Matsumoto, Mitsuhiro

AU - Suga, Moritaka

AU - Ando, Masayuki

AU - Saya, Hideyuki

PY - 1998/3

Y1 - 1998/3

N2 - We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

AB - We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

UR - https://www.scopus.com/pages/publications/0031882175

UR - https://www.scopus.com/pages/publications/0031882175#tab=citedBy

U2 - 10.3892/ijo.12.3.525

DO - 10.3892/ijo.12.3.525

M3 - Article

C2 - 9472088

AN - SCOPUS:0031882175

SN - 1019-6439

VL - 12

SP - 525

EP - 533

JO - International journal of oncology

JF - International journal of oncology

IS - 3

ER -

Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this